Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Role for MRD assessment in AL amyloidosis?

Bruno Paiva • 15 May 2020
COMy Virtual 2020
Amyloidosis Rare Diseases

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses whether there is a role for measurable residual disease (MRD) assessment in amyloid light-chain (AL) amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Bruno Paiva

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
2:08
Minimally invasive assessment of MRD in multiple myeloma
Bruno Paiva • 9 Dec 2023
2:34
Mutant hematopoietic progenitor cells in MM associated with secondary primary malignancies
Bruno Paiva • 9 Dec 2023
1:52
Clinical significance of MRD status in patients with MM treated with CAR-T and T-cell engagers
Bruno Paiva • 9 Dec 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals